Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAC Immune Ltd

AC Immune Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.26 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
91386
Market Cap
292.09M

Momentum Score

…

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.23
Low
2.33
High
52 Week Price Range
1.51
Low
4.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

AC Immune is a Swiss clinical-stage biopharmaceutical company focused on diagnostics and therapeutics for neurodegenerative proteinopathies, targeting tau and alpha-synuclein with antibody, vaccine and small-molecule platforms. Long-term growth drivers include clinical advancement of a diversified pipeline, platform-enabled candidate generation and persistent unmet need from aging populations, which may attract partnerships if data are positive.

Major risks are high clinical and regulatory uncertainty with binary trial outcomes, significant cash burn and financing needs, and intense competition in neurodegenerative drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.26
Dividend Yield
-
Revenue TTM
3.57M
Revenue Per Share
0.04
Gross Profit TTM
-52.86M
Debt / Equity
0.10
ROE
-89.65%
Net Debt
-22.28M
ROCE
-110.45%
Diluted EPS TTM
-0.89

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -70.45M -50.91M -54.22M -70.74M -72.99M
Net income -67.28M -50.92M -54.23M -70.75M -73.00M
Selling general administrative 11.65M 11.43M 10.58M 15.79M 10.88M
Gross profit 3.57M -35.26M -39.80M 3.94M -
Reconciled depreciation 2.50M 2.16M 2.21M 2.36M 2.41M
Ebit -65.86M -50.78M -54.05M -70.85M -79.01M
Ebitda -63.47M -48.62M -51.83M -70.78M -70.12M
Depreciation and amortization 2.39M 2.16M 2.21M 0.07M 8.89M
Operating income -68.86M -52.38M -53.62M -70.85M -79.01M
Other operating expenses 72.44M 79.69M 68.42M 74.78M 79.01M
Interest expense 0.18M 0.13M 0.18M 0.35M 0.58M
Tax provision 0.00M 0.00M 0.01M 0.01M 0.00M
Interest income 1.86M 3.20M 1.04M 0.07M 6.49M
Net interest income 1.67M 3.06M 0.87M -0.29M 5.90M
Income tax expense - 0.00M 0.01M 0.01M 0.00M
Total revenue 3.57M 27.31M 14.80M 3.94M 0.00M
Total operating expenses 72.44M 17.12M 13.82M 74.78M 79.01M
Cost of revenue - 62.57M 54.61M - -
Total other income expense net -1.58M 1.47M -0.60M 0.11M 6.02M
Net income from continuing ops -70.45M -50.92M -54.23M -70.75M -73.00M
Net income applicable to common shares - - - -70.75M -73.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 154.43M 230.91M 182.81M 185.94M 261.44M
Intangible assets 50.47M 50.42M 50.42M 50.42M 50.42M
Other current assets 4.63M 5.41M 7.06M 4.71M 4.42M
Total liab 109.49M 118.64M 22.17M 16.95M 29.46M
Total stockholder equity 44.93M 112.27M 160.64M 168.99M 231.98M
Other current liab 8.08M 97.15M 11.09M 9.42M 16.74M
Common stock 2.26M 2.23M 2.09M 1.80M 1.79M
Capital stock 2.25M 2.23M 2.09M 1.80M 1.79M
Retained earnings -439.52M -368.24M -316.20M -264.01M -200.94M
Other liab - - - 3.21M 7.10M
Other assets - - - 0.36M 0.36M
Cash 26.83M 36.27M 78.49M 31.59M 82.22M
Total current liabilities 94.80M 100.84M 13.58M 11.48M 20.03M
Current deferred revenue 83.80M 85.06M 0.14M 0.59M 0.72M
Net debt -22.28M -30.85M -75.00M -28.79M -79.31M
Short term debt 0.85M 1.03M 0.67M 0.55M 0.57M
Short long term debt total 4.55M 5.43M 3.50M 2.80M 2.91M
Other stockholder equity 482.19M 478.29M 474.80M 431.20M 431.13M
Property plant equipment - - - 7.07M 8.03M
Total current assets 96.83M 171.99M 125.15M 128.09M 202.63M
Long term investments 0.58M 0.41M 0.36M 0.36M 0.36M
Net tangible assets - - - 118.58M 181.56M
Short term investments 64.69M 129.21M 24.55M 91.00M 116.00M
Net receivables 0.68M 1.10M 15.67M 0.80M 1.40M
Inventory - - -0.62M - -1.40M
Accounts payable 2.07M 2.66M 1.68M 0.93M 2.00M
Accumulated other comprehensive income 0.01M -0.01M -0.05M 0.01M -
Non currrent assets other 0.00M 0.42M 0.36M 0.36M 0.36M
Non current assets total 57.59M 58.92M 57.66M 57.84M 58.81M
Capital lease obligations 4.54M 5.43M 3.50M 2.80M 2.91M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 64.60M -105.29M 65.64M 23.76M -53.66M
Change to liabilities - - - -1.20M 0.34M
Total cashflows from investing activities 60.69M -105.29M 65.64M 23.76M -53.66M
Net borrowings -1.03M -0.68M -0.55M -0.57M 22.95M
Total cash from financing activities -0.97M -1.12M 43.25M -1.35M 40.75M
Change to operating activities - - - -7.26M 6.60M
Net income -67.28M -50.92M -54.23M -70.75M -73.00M
Change in cash -4.92M -42.22M 46.91M -50.63M -78.68M
Begin period cash flow 31.75M 78.49M 31.59M 82.22M 160.89M
End period cash flow 26.83M 36.27M 78.49M 31.59M 82.22M
Total cash from operating activities -66.15M 65.84M -60.41M -73.57M -65.69M
Issuance of capital stock 0.01M 0.11M 43.80M 0.00M 16.72M
Depreciation 2.39M 2.16M 2.21M 2.36M 2.41M
Other cashflows from investing activities -0.16M -104.71M 66.45M 0.00M -0.03M
Change to account receivables 0.88M 13.55M -14.80M 0.04M -0.10M
Sale purchase of stock - - - -0.01M 0.00M
Other cashflows from financing activities 0.05M -0.55M 65.64M -0.77M 24.54M
Change to netincome - - - 3.26M -1.94M
Capital expenditures 0.86M 0.58M 0.80M 1.24M 2.63M
Change in working capital -6.47M 107.51M -15.16M -8.43M 6.84M
Stock based compensation 4.40M 5.47M 4.37M 3.33M 4.13M
Other non cash items 5.21M 1.61M 2.40M -0.07M -6.20M
Free cash flow -67.01M 65.27M -61.21M -74.81M -68.32M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ACIU
AC Immune Ltd		 -
-%		 2.26 - 11.24 81.75 5.14 39.78 -0.76
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

AC Immune Ltd

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Building B, Lausanne, Switzerland, 1015

41 21 345 91 21

https://www.acimmune.com

90

Name Title Year Born
Dr. Andrea Pfeifer Ph.D. Co-Founder, CEO & Director 1957
Mr. Piergiorgio Donati Chief Technical Operations Officer 1971
Dr. Marie Kosco-Vilbois Chief Scientific Officer 1958
Mr. Jean-Fabien Monin Chief Admin. Officer 1971
Prof. Johannes Rolf Streffer M.D. Chief Medical Officer 1969
Mr. Christopher Roberts Interim CFO & VP of Fin. NA
Mr. Joshua Drumm Ph.D. Head of Investor Relations NA
Mr. Alexandre Caratsch Gen. Counsel 1966
Judith Moore Global Head of Communications NA
Mr. Julian Snow VP of U.S. Fin. & Corp. Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…